A Phase 3 Open-label Study Evaluating the Long‑term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older Vertex Study Number: VX20-445-112.
The primary objective of the study is to evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor
(TEZ)/ivacaftor (IVA) in cystic fibrosis (CF) subjects 2 years of age and older
Study details
Study-ID: NCT05153317, 2020-002239-31
Study-ID: NCT05153317, 2020-002239-31
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BIH / Charité - Associated Partner
DZL Participating Sites: BIH / Charité - Associated Partner
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
